Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
Oryzon Genomics (BME: ORY) doses first patient in new MDS trial
Published by Arron Aatkar, PhD

Oryzon Genomics has announced that the first patient has been dosed in its new Phase Ib trial in myelodysplastic syndrome (MDS), led by the Medical College of Wisconsin. This study (NCT06502145) aims to evaluate the safety, tolerability and recommended Phase II dose of iadademstat when administered in combination with the standard-of-care, azacitidine, in adults with MDS.

Latest

TMT | Comment

Pinewood (LSE: PINE) buys Seez

Industrials | Comment

Metlen (ASE: MYTIL) FY24 Results

Healthcare | Comment

GSK’s (LSE: GSK) five-in-one vaccine approved by the FDA

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free